

REMARKS

AMENDMENTS TO THE SPECIFICATION

By this amendment, applicants have amended the specification by adding continuing data to the first paragraph. The inserted first paragraph makes reference to the priority applications for the subject application in accordance with 37 C.F.R. §1.78(a)(2)(iii). By the present amendment to the specification, no new matter has been added to the application. Applicants respectively request that this amendment to the specification be entered.

AMENDMENTS TO THE CLAIMS

Claims 1-33 were pending in the subject application. By this Preliminary Amendment, applicants have canceled claims 1-33, without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application, and added new claims 34-49.

Support for new claim 34 may be may be found inter alia in the specification, as originally-filed, on page 5, line 1-2. Support for new claim 35 may be may be found inter alia in the specification, as originally-filed, on page 19, line 13-14. Support for new claim 36 may be may be found inter alia in the specification, as originally-filed, on page 5, line 6-9, and page 8, line 10-23. Support for new claim 37 may be may be found inter alia in the specification, as originally-filed, on page 5, line 6-7, and page 7, line 17-25. Support for new claim 38 may be may be found inter alia in the specification, as originally-filed, on page 5, line 7 through page 6, line 2. Support for new claim 39 may be may be found inter alia in the specification, as originally-filed, on page 5, line 9-15, and page 6, line 31 through page 7, line 7. Support for new claim 40 may be may be found inter alia in the specification, as originally-filed, on page 6, line 4-6. Support for new claim 41 may be may be found inter alia in the specification, as originally-filed, on page 6, line 8-10. Support for new claim 42 may be may be found inter alia in the specification, as originally-filed,

on page 6, line 12-14. Support for new claim 43 may be may be found inter alia in the specification, as originally-filed, on page 7, line 27-29. Support for new claim 44 may be may be found inter alia in the specification, as originally-filed, on page 5, line 7 through page 6, line 2, page 5, line 6-7, and page 7, line 17-25. Support for new claim 45 may be may be found inter alia in the specification, as originally-filed, on page 5, line 20-23, and page 6, line 31 through page 7, line 7. Support for new claim 46 may be may be found inter alia in the specification, as originally-filed, on page 6, line 28-29. Support for new claim 47 may be may be found inter alia in the specification, as originally-filed, on page 5, line 6-9, and page 8, line 10-23. Support for new claim 48 may be may be found inter alia in the specification, as originally-filed, on page 6, line 31 through page 7, line 7. Support for new claim 49 may be may be found inter alia in the specification, as originally-filed, on page 5, line 20-23, and page 6, line 31 through page 7, line 7.

Applicants maintain that new claims 34-49 raise no issue of new matter and respectfully request that the amendment be entered. Accordingly, upon entry of this Amendment, claims 34-49 will be pending and under examination.

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following references be considered and made of record in the above-identified application.

1. Klaus P. Bogeso, et al., "Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindanes with Potential Atypical Antipsychotic Activity", Journal of Medicinal Chemistry, vol.38, No.22, 1995, pp. 4380-4392; and
2. EP 0 638 073 B1, published June 21, 2000.

The above-listed references 1 and 2 were cited in the International Search Report issued November 17, 2004 in connection with PCT/DK2004/000546. A copy of the International Search Report is attached hereto.

It is respectfully requested that the Examiner consider the cited references and that the copy of the enclosed Forms PTO/SB/08a and PTO/SB/08b be initialed and returned indicating that such information has been considered. Applicants respectfully request that the Examiner make the cited references of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee, other than the enclosed \$900.00 filing fee for the subject application, is deemed necessary in connection with filing this Preliminary Amendment. However, if an additional fee is required, authorization is hereby given to charge this fee, and any other fees not covered by the enclosed check to Deposit Account Number 50-3201.

Respectfully submitted,



Stephen G. Kalinchak
Registration No. 38,747
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 350-0781 (phone)
(201) 225-9571 (fax)